Gac Sanit. 2010 Sep-Oct;24(5):428-30. Epub 2010 Jul 8.

[Public financing of pharmaceuticals to quit smoking: utilisation and cost in Navarra, Spain (1995-2007)].

[Article in Spanish]

Azagra MJ, Echauri M, Pérez-Jarauta MJ, Marín P.

Source

Sección de Promoción de Salud, Instituto de Salud Pública de Navarra, Pamplona, España. mazagrar@cfnavarra.es

Abstract

The objective of this study was to assess the use of smoking cessation drugs and their cost in Navarre, where these pharmaceuticals are covered by the publicly funded health care system. Public coverage substantially increased the use of these drugs and their related expenditure. In 2007, consumption was four units of treatment per 100 smokers/year. The cost of pharmaceuticals for smoking cessation to the public health system can be estimated at 1.9 € per smoker/year, or 0.4 € per inhabitant/year. As the program has evolved, the main option for pharmaceutical treatment is nicotine replacement therapy. This financial effort does not seem to have had a populational impact on prevalence, although it is believed to have benefited many individual patients.

PMID:: 20619509; [PubMed - indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances

Publication Types

English Abstract

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Smoking - MedlinePlus Health Information

Molecular Biology Databases

Supplemental Content

Related citations

Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia. [Tob Control. 2007]
Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
Bertram MY, Lim SS, Wallace AL, Vos T. Tob Control. 2007 Aug; 16(4):255-60.
Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. [Clin Drug Investig. 2009]
Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S. Clin Drug Investig. 2009; 29(10):655-65.
Australian smokers' use of bupropion and nicotine replacement therapies and their relation to reimbursement, Australia 2001-05. [Drug Alcohol Rev. 2008]
Australian smokers' use of bupropion and nicotine replacement therapies and their relation to reimbursement, Australia 2001-05.
Lutsenko H, Doran CM, Hall WD. Drug Alcohol Rev. 2008 Mar; 27(2):160-4.
Review Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. [Pharmacoeconomics. 2010]
Review Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
Keating GM, Lyseng-Williamson KA. Pharmacoeconomics. 2010; 28(3):231-54.
Review Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. [Med Decis Making. 2002]
Review Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis.
Song F, Raftery J, Aveyard P, Hyde C, Barton P, Woolacott N. Med Decis Making. 2002 Sep-Oct; 22(5 Suppl):S26-37.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

[Public financing of pharmaceuticals to quit smoking: utilisation and cost in Na...
[Public financing of pharmaceuticals to quit smoking: utilisation and cost in Navarra, Spain (1995-2007)].
Gac Sanit. 2010 Sep-Oct ;24(5):428-30. Epub 2010 Jul 8 .

PubMed
Human herpesvirus 6B, complete genome
Human herpesvirus 6B, complete genome
gi|9633069|ref|NC_000898.1||gnl|NCB OMES|15112

Nucleotide
Prevalence of autoantibody-negative diabetes is not rare at all ages and increas...
Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity.
J Clin Endocrinol Metab. 2007 Jan ;92(1):88-92. Epub 2006 Oct 24 .

PubMed
Symptoms and findings predictive for the development of new retinal breaks.
Symptoms and findings predictive for the development of new retinal breaks.
Arch Ophthalmol. 2005 Apr ;123(4):479-84.

PubMed
Integrin activation involves a conformational change in the alpha 1 helix of the...
Integrin activation involves a conformational change in the alpha 1 helix of the beta subunit A-domain.
J Biol Chem. 2002 May 31 ;277(22):19800-5. Epub 2002 Mar 13 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: